menu
    • menu
    [{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"siRNA Lipid Conjugate-based Therapy","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Alys Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Gel","sponsorNew":"Alys Pharmaceuticals \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Alys Pharmaceuticals \/ Medicxi"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"JAK1 siRNA-lipid Conjugate","moa":"JAK1","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Alys Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Alys Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alys Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Alys Pharmaceuticals

    Menu

    Alys Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alys Pharmaceuticals

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Alys Pharmaceuticals

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JAK1 siRNA-lipid Conjugate

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alys Gets IND Clearance for Phase 2a Genetic Medicine Trial in Dermatology

                            Details : ALY-101 is an intradermal injectable JAK1 siRNA-lipid conjugate being investigated in patients suffering from Alopecia Areata (AA).

                            Product Name : ALY-101

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            February 04, 2025

                            Lead Product(s) : JAK1 siRNA-lipid Conjugate

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alys Pharmaceuticals

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Alys Pharmaceuticals

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : siRNA Lipid Conjugate-based Therapy

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Medicxi

                            Deal Size : $100.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Alys Pharmaceuticals Launches with $100M Financing from Medicxi for Immuno-Dermatology

                            Details : Alys will use the net proceeds to advance Immuno-Dermatology focused pipeline, including its siRNA lipid conjugate therapy for the treatment of atopic dermatitis.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 12, 2024

                            Lead Product(s) : siRNA Lipid Conjugate-based Therapy

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Medicxi

                            Deal Size : $100.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth